Navigation Links
RadMD Reaches 150th Clinical Trial

DOYLESTOWN, Penn., Oct. 5 /PRNewswire/ -- Completing a major milestone in its three years of operation, RadMD LLC ( announced that it has sourced readers for 150 clinical trials.

The most recent trial, conducted by ICON Medical Imaging for a leading pharmaceutical company, was designed to test the efficacy of a new treatment for metastatic kidney cancer. The trial used medical imaging to support the primary analysis of Progression Free Survival based on an independent central radiological review.

"The results of the reads showed that the drug delayed tumor growth by five months, with patients living twice as long without tumor growth as other cancer victims in the study's control arm. Ultimately, this provided the FDA with the information it needed to approve the drug," said Ted Gastineau, president and co-founder, ICON Medical Imaging. "Quality reads are critical and delays cost money and keep drugs from getting to the people who need it most. We are confident that RadMD's blinded readers have the skills and experience necessary to help us support our clients through the drug development process."

RadMD sourced five radiologists with a specialty in oncology within one week of the request and helped with resources and scheduling - allowing completion of the analysis ahead of schedule. Each radiologist received formalized training and extensive testing on a variety of topics related to the use of medical imaging in clinical trials from the company's Blinded Reader and Investigator Training Institute (BRITI)(TM). All CT scans, MRIs and bone scans obtained at baseline during the treatment period and the follow-up period were sent to the independent imaging core lab at ICON Medical Imaging.

Founded by medical imaging experts Kohkan Shamsi, MD, PhD, and Richard Patt, MD, RadMD sources clinical experts and provides consulting services for pharmaceutical, biotech and medical device trials and offers both CME-certified and non-CME courses on medical imaging in clinical trials for both on-site and offsite readers. The company's database of 600 readers come from multiple specialties including radiologists, pathologists, oncologists, cardiologists, medical physicists, medical technologists and others. RadMD has sourced readers for trials in cardiovascular, oncology, neurology, musculoskeletal, endocrinology and sports medicine.

"CRO's and pharmaceutical companies usually manage many concurrent trials and the availability of quality blinded readers saves money, decreases variability and expedites the trial process," said Dr. Shamsi. "By facilitating a key component of the clinical trial process, RadMD helps pharmaceutical, biotech and medical device companies reduce clinical development time, thus getting important anti-cancer and other treatments to the market more quickly."

For more information about RadMD, please visit or call 267-247-5544 ext. 500.

About RadMD

RadMD LLC ( provides consulting, training, and blinded reader services to the pharmaceutical and biotech industry. Services include defining and developing imaging strategies in clinical development programs, education and training through BRITI (the Blinded Reader & Investigator Training Institute), and the sourcing and management of blinded readers for clinical trials.

BRITI is a trademark of RadMD LLC.

This release, and additional RadMD resources, is available online in the Feintuch Communications media room at

    Pablo Andreu / Steph Johnson
    Feintuch Communications
    212.808.4903 / 212.808.4904 /


Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
3. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
4. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
5. CureHIV Reaches Out to Bill and Melinda Gates to Fund LiSAVIOR
6. Genmab Reaches Milestone in Ofatumumab Collaboration
7. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
8. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
9. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
10. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges
11. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
Post Your Comments:
(Date:10/12/2015)... , Oct. 12, 2015 Zimmer Biomet ... third quarter 2015 sales and earnings conference call will ... 29, 2015, at 8 a.m. Eastern Time.  A news ... at 7:30 a.m. Eastern Time the morning of the ... archived for replay following the conference call. --> ...
(Date:10/12/2015)... PARK, Calif. , Oct. 12, 2015 ... R&D and Chief Scientific Officer of Asterias ... biotechnology company in the emerging field of ... Dealmakers webcast, sponsored in part by Asterias ... Dr. Lebkowski will discuss the progress to ...
(Date:10/12/2015)... , Oct. 12, 2015 This study focuses ... and company profiles. In the two past decades, the industry ... of the manufacturing capabilities and rising consumer consumptions in ... society and economy. China is ... products. Far outpacing other economies in the world, ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... ... to an article published October 6th by the Herald Tribune, a recent study ... taken in 1988 has shown that it really is more difficult to lose weight these ... someone in 1971 would be on average 10 pounds heavier than their past counterpart. In ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... 19, 2015, high school aged female athletes, particularly in the area of track ... motion and mechanical overuse injuries than male peers in the same age group. ...
(Date:10/12/2015)... ... October 12, 2015 , ... According to an article published September ... an efficient way to save money on the healthcare needs of patients across the ... patients, house call visits can often effectively eliminate the need to go in and ...
(Date:10/12/2015)... ... October 12, 2015 , ... According to an article published ... San Antonio, Texas recommended that any high-rises in the city limits that do not ... forward. The article explains that it wasn’t until 1982 that the city started requiring ...
(Date:10/12/2015)... , ... October 12, 2015 , ... The Horizon Foundation ... initiatives focused on improving public health and enhancing the quality of life in the ... to 11 New Jersey non-profit organizations. , The charitable arm of Horizon Blue ...
Breaking Medicine News(10 mins):